PACB — Pacific Biosciences of California, Inc. stock price, charts and financials
QT33Pacific Biosciences of California, Inc.Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.43 | Insider Own | 6.73% | Shs Outstand | 310.60M | Perf Week | -15.00% |
| Market Cap | 368.06M | Forward P/E | - | EPS next Y | -0.47 | Insider Trans | -3.91% | Shs Float | 303.83M | Perf Month | -26.09% |
| Enterprise Value | 1.01B | PEG | - | EPS next Q | -0.13 | Inst Own | - | Short Float | 15.22% | Perf Quarter | -27.88% |
| Income | -131.36M | P/S | 2.31 | EPS this Y | 2.79% | Inst Trans | - | Short Ratio | 7.48 | Perf Half Y | -30.81% |
| Sales | 159.27M | P/B | - | EPS next Y | -11.96% | ROA | -17.48% | Short Interest | 46.24M | Perf YTD | -36.36% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -4961.74% | 52W High | 2.67 -56.41% | Perf Year | -13.77% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -23.75% | 52W Low | 1.07 9.17% | Perf 3Y | -90.50% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 7.72% 15.16% | Gross Margin | 35.97% | Volatility | 8.11% 6.34% | Perf 5Y | -96.30% |
| Dividend TTM | - | EV/Sales | 6.36 | EPS Y/Y TTM | 59.81% | Oper. Margin | -102.05% | ATR (14) | 0.10 | Perf 10Y | -86.16% |
| Dividend Ex-Date | - | Quick Ratio | 4.03 | Sales Y/Y TTM | 3.90% | Profit Margin | -82.49% | RSI (14) | 34.91 | Recom | 2.56 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.92 | EPS Q/Q | 80.00% | SMA20 | -14.70% | Beta | 2.27 | Target Price | 1.00 |
| Payout | 0.00% | Debt/Eq | - | Sales Q/Q | 0.00% | SMA50 | -18.39% | Rel Volume | 1.14 | Prev Close | 1.19 |
| Employees | 485 | LT Debt/Eq | 151.80 | Earnings | Feb 09 | SMA200 | -29.89% | Avg Volume | 6.46M | Price | 1.17 |
| IPO Date | Oct 27, 2010 | Option/Short | No / Yes | EPS/Sales Surpr. | 78.82% -6.92% | Net Debt/EBITDA | -5.68 | Volume | 7,344,452 | Change | -1.69% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Apr-14-26 | Reiterated | Barclays | Underweight | $1.50 → $1.00 |
| Mar-06-26 | Downgrade | Barclays | Equal Weight → Underweight | |
| Aug-08-25 | Reiterated | Bernstein | Outperform | $1.50 → $1.70 |
| Jun-25-25 | Reiterated | Barclays | Equal Weight | $2.00 → $1.50 |
| Nov-11-24 | Downgrade | UBS | Buy → Neutral | |
| Jun-03-24 | Reiterated | Jefferies | $4.00 | |
| May-13-24 | Reiterated | Piper Sandler | Neutral | $2.00 |
| May-10-24 | Reiterated | Barclays | Equal Weight | $2.00 |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral | |
| Apr-18-24 | Downgrade | Goldman Sachs | Buy → Neutral | $2.50 |
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 159 | 160 | 154 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 101 | 109 | 117 | — | — | — | — | — | — | |
| Gross Profit | 58 | 51 | 37 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 129 | 141 | 175 | — | — | — | — | — | — | |
| Research and Development | 89 | 97 | 135 | — | — | — | — | — | — | |
| Other Operating Expense | 2 | 370 | 202 | — | — | — | — | — | — | |
| Operating Income | -163 | -558 | -474 | — | — | — | — | — | — | |
| Interest Expense | 4 | 7 | 13 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 36 | 18 | 178 | — | — | — | — | — | — | |
| Net Income Before Taxes | -131 | -546 | -310 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -131 | -546 | -310 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -131 | -546 | -310 | — | — | — | — | — | — | |
| Net Income | -131 | -546 | -310 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.43 | -1.82 | -1.13 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.43 | -1.82 | -1.13 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.43 | -1.82 | -1.07 | — | — | — | — | — | — | |
| EBITDA | -114 | -34 | -243 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.28 | 3.51 | 3.26 | — | — | — | — | — | — | |
| Gross Margin | 36.48 | 31.87 | 24.03 | — | — | — | — | — | — | |
| Operating Margin | -102.52 | -348.75 | -307.79 | — | — | — | — | — | — | |
| Net Margin | -82.39 | -341.25 | -201.30 | — | — | — | — | — | — | |
| Shares Outstanding | 311 | 300 | 274 | — | — | — | — | — | — | |
| Market Capitalization | 362 | 561 | 501 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Gibson James R II | See Remarks | Apr 01 '26 | Sale | 1.37 | 88,185 | 120,813 | 1,245,663 | Apr 03 |
| HENRY CHRISTIAN O | See Remarks | Mar 03 '26 | Sale | 1.51 | 12,497 | 18,920 | 3,581,813 | Mar 04 |
| Van Oene Mark | See Remarks | Mar 03 '26 | Sale | 1.51 | 6,504 | 9,847 | 2,243,634 | Mar 04 |
| Farmer Michele | See Remarks | Mar 03 '26 | Sale | 1.51 | 2,979 | 4,510 | 305,948 | Mar 04 |
| HENRY CHRISTIAN O | See Remarks | Feb 18 '26 | Sale | 1.63 | 140,874 | 229,484 | 2,673,500 | Feb 19 |
| Farmer Michele | See Remarks | Feb 18 '26 | Sale | 1.63 | 14,952 | 24,357 | 219,092 | Feb 19 |
| Van Oene Mark | See Remarks | Feb 18 '26 | Sale | 1.63 | 55,107 | 89,769 | 1,742,638 | Feb 19 |
| Farmer Michele | See Remarks | Feb 17 '26 | Sale | 1.58 | 35,215 | 55,499 | 234,044 | Feb 19 |
| Van Oene Mark | See Remarks | Feb 17 '26 | Sale | 1.58 | 129,790 | 204,549 | 1,797,745 | Feb 19 |
| HENRY CHRISTIAN O | See Remarks | Feb 17 '26 | Sale | 1.58 | 331,793 | 522,906 | 2,814,374 | Feb 19 |
| Van Oene Mark | See Remarks | Aug 18 '25 | Sale | 1.31 | 26,836 | 35,182 | 1,920,035 | Aug 20 |
| Farmer Michele | See Remarks | May 19 '25 | Sale | 1.00 | 5,195 | 5,200 | 269,259 | May 21 |
| HENRY CHRISTIAN O | See Remarks | Mar 03 '25 | Sale | 1.41 | 12,497 | 17,583 | 2,225,357 | Mar 05 |
| Van Oene Mark | See Remarks | Mar 03 '25 | Sale | 1.41 | 6,486 | 9,126 | 1,497,695 | Mar 05 |
| Farmer Michele | See Remarks | Mar 03 '25 | Sale | 1.41 | 2,973 | 4,183 | 184,619 | Mar 05 |